Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX)

Geode Capital Management LLC lifted its position in shares of OncoCyte Co. (NASDAQ:OCX) by 31.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,069 shares of the company’s stock after acquiring an additional 33,089 shares during the quarter. Geode Capital Management LLC owned approximately 0.81% of OncoCyte worth $326,000 at the end of the most recent reporting period.

Separately, FNY Investment Advisers LLC raised its position in shares of OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company’s stock valued at $117,000 after acquiring an additional 6,481 shares during the last quarter. Institutional investors own 55.35% of the company’s stock.

Wall Street Analyst Weigh In

OCX has been the subject of a number of analyst reports. Lake Street Capital initiated coverage on OncoCyte in a research note on Friday, March 28th. They set a “buy” rating and a $5.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a research report on Tuesday, April 8th. StockNews.com assumed coverage on shares of OncoCyte in a research report on Sunday, April 6th. They issued a “sell” rating on the stock. Finally, Stephens restated an “equal weight” rating and set a $4.00 price objective on shares of OncoCyte in a report on Tuesday, March 25th.

Insider Transactions at OncoCyte

In other news, major shareholder Patrick W. Smith acquired 1,077,600 shares of OncoCyte stock in a transaction dated Friday, February 7th. The stock was bought at an average cost of $2.05 per share, with a total value of $2,209,080.00. Following the completion of the transaction, the insider now directly owns 2,872,671 shares of the company’s stock, valued at approximately $5,888,975.55. This represents a 60.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrea S. James bought 97,561 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the transaction, the chief financial officer now owns 151,231 shares in the company, valued at $310,023.55. The trade was a 181.78 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 1,175,186 shares of company stock valued at $2,409,131 over the last quarter. Corporate insiders own 1.58% of the company’s stock.

OncoCyte Trading Down 2.3 %

NASDAQ:OCX opened at $3.03 on Friday. OncoCyte Co. has a 1 year low of $1.92 and a 1 year high of $4.75. The stock has a 50-day moving average price of $3.17 and a two-hundred day moving average price of $2.71. The stock has a market cap of $86.65 million, a price-to-earnings ratio of -0.69 and a beta of 0.97.

OncoCyte (NASDAQ:OCX) last posted its earnings results on Monday, March 24th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.88. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The business had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.